These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39154822)

  • 1. Topiroxostat improves glomerulosclerosis in type 2 diabetic Nagoya Shibata Yasuda mice with early diabetic kidney disease.
    Hagiwara M; Ishiyama S; Nakamura T; Mochizuki K
    Eur J Pharmacol; 2024 Nov; 982():176915. PubMed ID: 39154822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
    Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
    Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
    Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
    Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Bone Strength and Metabolism in Type 2 Diabetic Model Nagoya Shibata Yasuda Mice.
    Tanaka H; Miura T; Yamashita T; Yoneda M; Takagi S
    Biol Pharm Bull; 2018 Oct; 41(10):1567-1573. PubMed ID: 30012927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
    Nakamura T; Nampei M; Murase T; Satoh E; Akari S; Katoh N; Mizukami H
    Nutr Diabetes; 2021 Apr; 11(1):12. PubMed ID: 33850106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin.
    Zhang Y; Fukusumi Y; Kayaba M; Nakamura T; Sakamoto R; Ashizawa N; Kawachi H
    Nefrologia (Engl Ed); 2021; 41(5):539-547. PubMed ID: 36165136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of myristic acid improves hyperglycaemia in the Nagoya-Shibata-Yasuda mouse model of congenital type 2 diabetes.
    Takato T; Iwata K; Murakami C; Wada Y; Sakane F
    Diabetologia; 2017 Oct; 60(10):2076-2083. PubMed ID: 28707095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin secretion to glucose as well as nonglucose stimuli is impaired in spontaneously diabetic Nagoya-Shibata-Yasuda mice.
    Hamada Y; Ikegami H; Ueda H; Kawaguchi Y; Yamato E; Nojima K; Yamada K; Babaya N; Shibata M; Ogihara T
    Metabolism; 2001 Nov; 50(11):1282-5. PubMed ID: 11699045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous amyloidosis in senile NSY mice.
    Shimizu K; Morita H; Niwa T; Maeda K; Shibata M; Higuchi K; Takeda T
    Acta Pathol Jpn; 1993 May; 43(5):215-21. PubMed ID: 8322607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
    Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Hisamichi M; Hirata K; Kimura K; Shibagaki Y
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1366-76. PubMed ID: 27029427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
    Wada T; Hosoya T; Honda D; Sakamoto R; Narita K; Sasaki T; Okui D; Kimura K
    Clin Exp Nephrol; 2018 Aug; 22(4):860-870. PubMed ID: 29372470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.
    Takahashi K; Mizukami H; Osonoi S; Ogasawara S; Hara Y; Kudoh K; Takeuchi Y; Sasaki T; Daimon M; Yagihashi S
    Neurobiol Dis; 2021 Jul; 155():105392. PubMed ID: 34000416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Topiroxostat on Reducing Oxidative Stress in the Aorta of Streptozotocin-Induced Diabetic Rats.
    Noda M; Kikuchi C; Tarui R; Nakamura T; Murase T; Hori E; Matsunaga T
    Biol Pharm Bull; 2023 Feb; 46(2):272-278. PubMed ID: 36529499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor γ Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice.
    Ochiai M; Takeuchi T; Nozaki T; Ishihara KO; Matsuo T
    J Food Sci; 2019 Feb; 84(2):339-348. PubMed ID: 30726580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hepatic gene expression profile in a spontaneous mouse model of type 2 diabetes under a high sucrose diet.
    Nojima K; Sugimoto K; Ueda H; Babaya N; Ikegami H; Rakugi H
    Endocr J; 2013; 60(3):261-74. PubMed ID: 23131898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NSY mouse: a new animal model of spontaneous NIDDM with moderate obesity.
    Ueda H; Ikegami H; Yamato E; Fu J; Fukuda M; Shen G; Kawaguchi Y; Takekawa K; Fujioka Y; Fujisawa T
    Diabetologia; 1995 May; 38(5):503-8. PubMed ID: 7489831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Egg White Hydrolysate Improves Glucose Tolerance in Type-2 Diabetic NSY Mice.
    Ochiai M; Azuma Y
    J Nutr Sci Vitaminol (Tokyo); 2017; 63(6):422-429. PubMed ID: 29332905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose effect and mode of inheritance of diabetogenic gene on mouse chromosome 11.
    Babaya N; Ueda H; Noso S; Hiromine Y; Nojima K; Itoi-Babaya M; Kobayashi M; Fujisawa T; Ikegami H
    J Diabetes Res; 2013; 2013():608923. PubMed ID: 23671880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
    Kato S; Ando M; Mizukoshi T; Nagata T; Katsuno T; Kosugi T; Tsuboi N; Maruyama S
    Nagoya J Med Sci; 2016 May; 78(2):135-42. PubMed ID: 27303100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study.
    Fujishima Y; Nishizawa H; Kawachi Y; Nakamura T; Akari S; Ono Y; Fukuda S; Kita S; Maeda N; Hoshide S; Shimomura I; Kario K
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.